Provided by Tiger Trade Technology Pte. Ltd.

Janux Therapeutics, Inc.

15.86
-18.1300-53.34%
Post-market: 15.980.1200+0.76%17:09 EST
Volume:15.89M
Turnover:272.33M
Market Cap:953.94M
PE:-9.44
High:18.86
Open:18.51
Low:15.77
Close:33.99
52wk High:71.71
52wk Low:15.77
Shares:60.15M
Float Shares:44.97M
Volume Ratio:8.34
T/O Rate:35.35%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.6802
EPS(LYR):-1.2836
ROE:-12.48%
ROA:-10.49%
PB:0.98
PE(LYR):-12.36

Loading ...

Small U.S. Stocks Finish Mixed As Falcon's Beyond Global Leads, Janux Therapeutics Lags

Dow Jones
·
49 mins ago

Top Midday Decliners

MT Newswires Live
·
2 hours ago

Gold Down Over 1%; Signet Shares Fall After Q3 Results

Benzinga
·
4 hours ago

BUZZ-U.S. STOCKS ON THE MOVE-Bristol Myers Squibb, Cloudflare, Boeing

Reuters
·
Yesterday

BUZZ-U.S. STOCKS ON THE MOVE-Janux Therapeutics, Bunge Global, Shopify

Reuters
·
Yesterday

Signet Jewelers, Janux Therapeutics, BW LPG And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session

Benzinga_recent_news
·
Yesterday

Wedbush Cuts Price Target on Janux Therapeutics to $45 From $76, Keeps Outperform Rating

MT Newswires Live
·
Yesterday

Janux Therapeutics Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
Yesterday

Janux Therapeutics Inc : Stifel Cuts Target Price to $38 From $46

THOMSON REUTERS
·
Yesterday

BUZZ-Janux plunges after early-stage data for prostate cancer drug

Reuters
·
Yesterday

Janux Therapeutics Shares Down 44.3% Premarket After Co Reports Early-Stage Prostate Cancer Drug Trial Data

THOMSON REUTERS
·
Yesterday

Janux Therapeutics Reports Positive Phase 1 Results for JANX007 in mCRPC Patients

Reuters
·
Yesterday

Janux Announces Encouraging Efficacy and Safety Profile From Ongoing Phase 1 Clinical Trial for Janx007 in Mcrpc

THOMSON REUTERS
·
Yesterday

Janux Therapeutics Inc - Deep Psa Reductions and Promising Crs Profile in Phase 1B Study

THOMSON REUTERS
·
Yesterday

Janux Therapeutics Inc - Janx007 Shows Manageable Safety Profile With Crs Limited to Cycle 1

THOMSON REUTERS
·
Yesterday

Janux Therapeutics Price Target Maintained With a $70.00/Share by HC Wainwright & Co.

Dow Jones
·
Nov 25

Janux Therapeutics Announces Updated Phase 1 Clinical Data for JANX007 in Prostate Cancer

Reuters
·
Nov 24

Is Progress in Prostate Cancer Therapies and Shrinking Losses Altering the Investment Case for Janux Therapeutics (JANX)?

Simply Wall St.
·
Nov 18

Janux Therapeutics Chief Business Officer Andrew Hollman Meyer Reports Disposal of Common Shares

Reuters
·
Nov 15

Positive Outlook on Janux Therapeutics Inc. Driven by Promising Prostate Cancer Developments and Strong Financial Position

TIPRANKS
·
Nov 12